These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30840967)

  • 1. Ivabradine in Cancer Treatment-Related Left Ventricular Dysfunction.
    Sarocchi M; Arboscello E; Ghigliotti G; Murialdo R; Bighin C; Gualandi F; Sicbaldi V; Balbi M; Brunelli C; Spallarossa P
    Chemotherapy; 2018; 63(6):315-320. PubMed ID: 30840967
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic review and meta-analysis of beta-blockers and renin-angiotensin system inhibitors for preventing left ventricular dysfunction due to anthracyclines or trastuzumab in patients with breast cancer.
    Lewinter C; Nielsen TH; Edfors LR; Linde C; Bland JM; LeWinter M; Cleland JGF; Køber L; Braunschweig F; Mansson-Broberg A
    Eur Heart J; 2022 Jul; 43(27):2562-2569. PubMed ID: 34951629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Left ventricular dysfunction in patients receiving cardiotoxic cancer therapies are clinicians responding optimally?
    Yoon GJ; Telli ML; Kao DP; Matsuda KY; Carlson RW; Witteles RM
    J Am Coll Cardiol; 2010 Nov; 56(20):1644-50. PubMed ID: 21050974
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of anthracycline and trastuzumab-induced decline in left ventricular ejection fraction with angiotensin-converting enzyme inhibitors or angiotensin receptor blocker: a narrative systematic review of randomised controlled trials.
    Lee S; Alsamarrai A; Xiao A; Wang TKM
    Intern Med J; 2024 Aug; 54(8):1254-1263. PubMed ID: 38874281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardioprotective effect of renin-angiotensin inhibitors and β-blockers in trastuzumab-related cardiotoxicity.
    Ohtani K; Ide T; Hiasa KI; Sakamoto I; Yamashita N; Kubo M; Tsutsui H
    Clin Res Cardiol; 2019 Oct; 108(10):1128-1139. PubMed ID: 30859381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of cardio-protective agents in cardio-preservation in breast cancer patients receiving Anthracyclines ± Trastuzumab: a Meta-analysis of clinical studies.
    Elghazawy H; Venkatesulu BP; Verma V; Pushparaji B; Monlezun DJ; Marmagkiolis K; Iliescu CA
    Crit Rev Oncol Hematol; 2020 Sep; 153():103006. PubMed ID: 32777728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation/Dose Reduction of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers during Acute Decompensated Heart Failure in African-American Patients with Reduced Left-Ventricular Ejection Fraction.
    Kane JA; Kim JK; Haidry SA; Salciccioli L; Lazar J
    Cardiology; 2017; 137(2):121-125. PubMed ID: 28376504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ivabradine treatment in a chronic heart failure patient cohort: symptom reduction and improvement in quality of life in clinical practice.
    Zugck C; Martinka P; Stöckl G
    Adv Ther; 2014 Sep; 31(9):961-74. PubMed ID: 25160945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of heart FailUre medical Treatment after hospital discharge according to left ventricUlaR Ejection fraction: the FUTURE survey.
    Cohen Solal A; Leurs I; Assyag P; Beauvais F; Clerson P; Contre C; Thebaut JF; Genoun M;
    Arch Cardiovasc Dis; 2012; 105(6-7):355-65. PubMed ID: 22800720
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials.
    Fox K; Komajda M; Ford I; Robertson M; Böhm M; Borer JS; Steg PG; Tavazzi L; Tendera M; Ferrari R; Swedberg K
    Eur Heart J; 2013 Aug; 34(29):2263-70. PubMed ID: 23536611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-life indications to ivabradine treatment for heart rate optimization in patients with chronic systolic heart failure.
    Tondi L; Fragasso G; Spoladore R; Pinto G; Gemma M; Slavich M; Godino C; Salerno A; Montanaro C; Margonato A
    J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):351-356. PubMed ID: 29762337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis.
    Gao Y; Wang R; Jiang J; Hu Y; Li H; Wang Y
    Heart Fail Rev; 2023 Nov; 28(6):1405-1415. PubMed ID: 37414918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?
    Oliva S; Cioffi G; Frattini S; Simoncini EL; Faggiano P; Boccardi L; Pulignano G; Fioretti AM; Giotta F; Lestuzzi C; Maurea N; Sabatini S; Tarantini L;
    Oncologist; 2012; 17(7):917-24. PubMed ID: 22673631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nurse-coordinated collaborative disease management improves the quality of guideline-recommended heart failure therapy, patient-reported outcomes, and left ventricular remodelling.
    Güder G; Störk S; Gelbrich G; Brenner S; Deubner N; Morbach C; Wallenborn J; Berliner D; Ertl G; Angermann CE
    Eur J Heart Fail; 2015 Apr; 17(4):442-52. PubMed ID: 25727879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response of doxorubicin-induced cardiomyopathy to the current management strategy of heart failure.
    Tallaj JA; Franco V; Rayburn BK; Pinderski L; Benza RL; Pamboukian S; Foley B; Bourge RC
    J Heart Lung Transplant; 2005 Dec; 24(12):2196-201. PubMed ID: 16364871
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of the safety of continuing trastuzumab despite overt left ventricular dysfunction.
    Barron CC; Alhussein MM; Kaur U; Cosman TL; Tyagi NK; Brown M; Mukherjee SD; Ellis PM; Dhesy-Thind S; Leong DP
    Curr Oncol; 2019 Aug; 26(4):240-246. PubMed ID: 31548803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-Blockers and ACE Inhibitors Are Associated with Improved Survival Secondary to Ventricular Tachyarrhythmia.
    Schupp T; Behnes M; Weiß C; Nienaber C; Lang S; Reiser L; Bollow A; Taton G; Reichelt T; Ellguth D; Engelke N; Ansari U; El-Battrawy I; Bertsch T; Akin M; Mashayekhi K; Borggrefe M; Akin I
    Cardiovasc Drugs Ther; 2018 Aug; 32(4):353-363. PubMed ID: 30074111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and safety of ivabradine in Chinese patients with chronic heart failure: an observational study.
    Zhou J; Xu Y; Zheng Z; Zhang S; Yang J; Zhang Y; Tang B; Han H; Zhang Q; Liu F; Ding W; Qian C; Su G; Liu X; Shen Y; Shi B; Kong X; Ge Z; Zhang P; Guo X; Zhang H; Sun Y; Dong Y; Fu G; Feng L; Ge J;
    ESC Heart Fail; 2024 Apr; 11(2):846-858. PubMed ID: 38193606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of prophylactic betablocker or ACE inhibitor on cardiac dysfunction & heart failure during anthracycline chemotherapy ± trastuzumab.
    Gujral DM; Lloyd G; Bhattacharyya S
    Breast; 2018 Feb; 37():64-71. PubMed ID: 29101824
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological treatment patterns in heart failure: a population-based cohort study.
    Bosco-Lévy P; Favary C; Jové J; Lassalle R; Moore N; Droz-Perroteau C
    Eur J Clin Pharmacol; 2020 Jan; 76(1):97-106. PubMed ID: 31637454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.